公开(公告)号：WO2017132749A1

公开(公告)日：2017-08-10

申请号：PCT/CA2017/000025

申请日：2017-02-06

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： WANG, Jean ,  DICK, John ,  NG, Stanley ,  MINDEN, Mark ,  MITCHELL, Amanda ,  CHEN, Weihsu, Claire ,  ZANDSTRA, Peter ,  KENNEDY, James

IPC: C40B40/06 ,  C12Q1/68 ,  C40B30/04 ,  C40B40/08 ,  G01N33/48 ,  G06F19/10 ,  G06F19/20

CPC classification number: G01N33/57426 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158 ,  C40B40/06 ,  C40B40/08 ,  G01N2800/52 ,  G06F19/10 ,  G06F19/20

Abstract: There is described herein a method of prognosing or classifying a subject with acute myeloid leukemia (AML) comprising: (a) determining the expression level of at least 3 genes in a test sample from the subject selected from the group consisting of DNMT3B, ZBTB46, NYNRIN, ARHGAP22, LAPTM4B, MMRN1, DPYSL3, KIAAQ125. CDK6, CPXM1, SOCS2, SMIM24, EMP1, NGFRAP1, CD34, AKR1C3, GPR56; and (b) comparing expression of the at least 3 genes in the test sample with reference expression levels of the at least 3 genes from control samples from a cohort of patients; wherein a difference or similarity in the expression of the at least 3 genes in the test sample and the reference expression levels is used to prognose or classify the subject with AML into a low risk group or a high risk group for worse survival.

Abstract translation: 本文描述了预测或分类患有急性骨髓性白血病（AML）的受试者的方法，其包括：（a）确定来自选自以下的对象的测试样品中的至少3个基因的表达水平： 由DNMT3B，ZBTB46，NYNRIN，ARHGAP22，LAPTM4B，MMRN1，DPYSL3，KIAAQ125组成的组。 CDK6，CPXM1，SOCS2，SMIM24，EMP1，NGFRAP1，CD34，AKR1C3，GPR56; 和（b）比较测试样品中至少3种基因的表达与来自一组患者对照样品的至少3种基因的参考表达水平; 其中使用测试样品中至少3种基因的表达和参考表达水平的差异或相似性来预测或分类具有AML的受试者成为低风险组或高风险组以生存更差。

公开(公告)号：EP3411517A1

公开(公告)日：2018-12-12

申请号：EP17746659.6

申请日：2017-02-06

Applicant: University Health Network

Inventor： WANG, Jean ,  DICK, John ,  NG, Stanley ,  MINDEN, Mark ,  MITCHELL, Amanda ,  CHEN, Weihsu, Claire ,  ZANDSTRA, Peter ,  KENNEDY, James

IPC: C40B40/06 ,  C12Q1/68 ,  C40B30/04 ,  C40B40/08 ,  G01N33/48 ,  G06F19/10 ,  G06F19/20

CPC classification number: G01N33/57426 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158 ,  C40B40/06 ,  C40B40/08 ,  G01N2800/52 ,  G06F19/10 ,  G06F19/20

Abstract: There is described herein a method of prognosing or classifying a subject with acute myeloid leukemia (AML) comprising: (a) determining the expression level of at least 3 genes in a test sample from the subject selected from the group consisting of DNMT3B, ZBTB46, NYNRIN, ARHGAP22, LAPTM4B, MMRN1, DPYSL3, KIAAQ125. CDK6, CPXM1, SOCS2, SMIM24, EMP1, NGFRAP1, CD34, AKR1C3, GPR56; and (b) comparing expression of the at least 3 genes in the test sample with reference expression levels of the at least 3 genes from control samples from a cohort of patients; wherein a difference or similarity in the expression of the at least 3 genes in the test sample and the reference expression levels is used to prognose or classify the subject with AML into a low risk group or a high risk group for worse survival.